

October 7, 2025  
Kidswell Bio Corporation (TSE:4584)  
S-Quatre Corporation  
PR Release

**SHED Clinical Study for Cerebral Palsy  
Data Safety Monitoring Board Confirms “No Safety Concerns”**

Tokyo, October 7, 2025 - Kidswell Bio Group is engaged in the research and development of novel cell-based therapies (regenerative medicine products) utilizing stem cells from human exfoliated deciduous teeth (SHED), with the aim of developing new treatments for pediatric and rare diseases for which no effective therapies currently exist.

In the clinical trial entitled “A clinical trial to evaluate the safety and tolerability of stem cells from human exfoliated deciduous teeth in children with cerebral palsy”, led by Nagoya University and jointly conducted with our subsidiary, S-Quatre Corporation, the Data Safety Monitoring Board (DSMB)—an independent body distinct from the research institution—convened to review safety outcomes in accordance with the study protocol. The DSMB assessed safety data collected over the four-week period following administration and concluded that no adverse events were observed related to intravenous administration of autologous SHED, demonstrating successful attainment of the primary endpoint. This outcome indicates the steady progress of this clinical study and represents an important milestone that will further support upcoming clinical trial of allogeneic SQ-SHED.

An interim analysis of efficacy data is currently underway, with results expected to be announced by Nagoya University within 2025. Our group will continue advancing research and development to establish innovative therapies for cerebral palsy and other intractable diseases.

■ Related release

[Administration Completed in All Three Patients in Clinical Study Using SHED for the Treatment of Pediatric Cerebral Palsy](#), June 24, 2025

---

Disclaimer: This English translation is provided for reference purposes only. Should any discrepancies arise between this translation and the original Japanese document, the original Japanese document shall take precedence.